• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:SU841588A3
    申请号:SU782699049
    申请日:1978-12-13
    公开日:1981-06-23
    发明作者:Труммлитц Гюнтер；Энгель Вольфхард；Зеегер Эрнст；Энгельхардт Гюнтер
    申请人:Д-Р Карл Томэ Гмбх (Фирма)；
    IPC主号:
    专利说明:

    where R. is a hydrogen atom or a protective alkyl group; R and Y have the above values, are reacted with an aromatic amine of the general formula ".4J where R, has the above values in an inert organic solvent or in excess of an amine of general formula III at a temperature of from 20 to 200 ° C. In the case of using a carboxylic acid ester of the formula II, the alcohol or feNOL obtained by the reaction is removed by azeotropic distillation or by heating under reflux, for example, using a Soxhlet extractor equipped with a molecular sieve. The product crystallizes directly from the reaction mixture or using a water-miscible solvent with the addition of water. If an amide compound of formula P is used, the process is carried out in the presence of catalytic amounts of P-toluenesulfonic acid and the aromatic amine is taken in excess. At the same time, the tacTo crystallizes the product directly from the reaction mixture. The target product is isolated by evaporation of the solvent or by precipitation by adding water using a solvent miscible with water. In some cases, when the 4-hydroxy group is protected in the compound of the general formula P before carrying out this process, the protective group is cleaved again after the interaction. So, for example, before the ester-feedyrugot 4-hydroxy reaction, the corresponding alkoxy group, for example, the alkoxy group with 1-8 carbon atoms and, after reacting, this protective group is cleaved off by treatment with a mineral acid, such as hydrochloric acid, at a temperature from 0 to 100 ° C or treatment with a boron trihydride in an inert solvent, such as ac chlorinated hydrocarbon, at a temperature of minus 80 to plus. . The interaction of carboxylic acid derivatives of general formula II with ami. SG formula ni is carried out in an inert organic solvent such as aromatic of hydrocarbons, such as benzene, toluene, xylene, chlorobenzene, o-dihlorbenz6l or tetrahydronaphthalene, dimethylacetamide, dimethylsulfoxide or hexamethylphosphoric triamide in ethers such as dimetok STsaH, diethylene glycol dimethyl fir or diphenyl ether at a temperature of from 60 to. If an ester of the compound of formula II is used, then the process is conducted in a {1 temperature from 20 to. The reaction is preferably carried out in o-ol or xylene at boiling. The compounds of general formula I, if necessary, can be converted into their salts with inorganic or organic bases. Suitable bases are, for example, an alkali metal alcoholate, an alkali or alkaline earth metal hydroxide, a trialkylammonium hydroxide, an alkylamine, preferably an amino alcohol, in particular N-methyl-O-glucamine. Example 1. 4-Oxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide. 26.9 g (0.1 mol) of 4-hydroxy-2-methyl-2H-1, 2-benzothiazine-3-carboxylic acid methyl 1,1-dioxide and 12.5 g (0.11 mol) of 2- Amino-5-methylthiazole in 4 p xylene is heated under reflux for 24 hours under a nitrogen atmosphere. The methanol produced in this way is removed by means of a molecular sieve (4 A) contained in a Soxhlet apparatus. The hot reaction solution is filtered. After cooling and settling overnight, the crude product crystallized out of the filtrate (32.0 g, 91%). After recrystallization from ethylene chloride, 26.0 g (74%) of 4-hydroxy-2-methyl-N- (5-methyl-2-thiazopyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide are obtained. from m.p. 254 ° C (decomp.); 1 H-NMR (D (, - DMSO): 0 8.2-7.8 (m, 4.5-H to 8-H); 7, Zb (d, 1, and 0.75 Hz, 4- H); 2.90 (C3, B-CH3); 2, 3b (d, 3, J 0.75 Hz, 5-СН); and 2 exchange protons. Calculated,%: C 47.85; H 3.73; N 1.96; S 18.21. "" S ° 4S2. (351.40); Found,%: C 47.65; .H 3.72; N 11.72; S 18.40 Example 2. Sodium salt of 4-oxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide. To a solution of 1.1 g 20 mmol; sodium methoxide in 200 ml of methanol was added 7.0 g (20 mmol) of 4-hydroxy-2-methyl-L- (5-methyl-2-thiazolyl) -2H-1, 2-benzothiazine-3-carboximide -1,1 dioxide, heated and the resulting yellow solution is filtered, evaporated in vacuo to dryness. The residue is mixed with acetone and p ether, filtered and get 7.25 g (97.5%) of the sodium salt of 4-hydroxy-2-methyl-M- (5-, methyl-2-thiazolyl) -2H-1,2-benzothiazine-3- carboxamide-1, 1-dioxide with mp (decomp.).
    P. r and me 3, M-Methyl-O-Glucamine salt of 4-hydroxy-2-methyl-M- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1 , 1-dioxide.
    6.0 g (17.1 mmol) of 4-hydroxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide and 3, 33 g (17.1 mmol) of N-methyl-D-glucamine are dissolved in 1 liter of distilled water. After heating to 60 ° C, the solution is filtered. The filtrate is evaporated in vacuo to 60 ml. Remove the luyus M-methyl-O-glucamine salt of 4-hydroxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide and filter out in vacuum at 80 ° C over phosphorus oxide. Obtain 5.2 g (56%), so pl. .
    Calculated,%: C 46.14; H 5.53 / N10.25; S 11.73. (546.63)

    C 45.95 H 5.76% Found: N10.24 S 11.98.
    Example 4. 4-Oxy-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide.
    Prepared from 4-OXY-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide and 2-amino-5-methylthiazole as in the same way as an example. Crude product (65% -) is purified by chromatography on a column (Merck silica gel -60, grain size: 0.20, 5 mm) using chloroform / ethanol (97: 3 as eluate and get 4-oKCH-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine -3-carboxamide-1, 1-dioxide with a yield of 31%, mp 233-C (decomp.) From ethylene chloride.
    Calculated,%: C 46.29; H 3.29; N 12.45; S 19.01
    C H M-Od (337.38)
    Nag.den,%: C 46.20; H 3.34; N 12.52; N 19.12.
    Example 5. 2 Ethyl-4-hydroxy-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide.,
    Prepared from 2-ethyl-4-oxy-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide methyl ester and 2-amino-5-methylthiazole analogously to Example 1 in 82% yield, m.p. (different from xylene.
    Calculated,%: C 49.30; H 4.14; N 11.50; S 17.55,
    Cts-H NjO 82 (365.43)
    Found,%: C 49.2-5; H 4.07; N 11.40; S 17-, 72.
    Example 6. N- (5-ethyl-2-thiazolyl) -4-hydroxy-2-methyl-2n-1,2-benzothiazine-3-carboxamide-1, 1-dioxide.
    Prepared from methyl 4-hydroxy-2-methyl-2H-1, 2-benzothiazine-3-carboxylic acid 1,1-dioxide and 5-ethyl-2-aminothiazole in a similar manner
    Example 1 with a yield of 67%, so pl. (decomp.) of xylene.
    Calculated,%: C 49.30; H 4.14;
    N 11.50; S 17.55.
     ° 4-5g (365.43) 5 Found,%: C 49.20; H 4.19;
    N 11.30; S 17.63, Example 7. 4-Oxy-2-methyl-N- (5-n-propyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-di-QQ oxide. .
    Prepared from methyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide and 2-amino-5-n-propyl thiazole in toluene, as in Example 1, in 48% yield, m.p. (decomp.) of dioxane (petroleum ether).
    Calculated,%: C 50.64; H 4.52; N 11.07; S 16.90. H (379.46;
    20
    Found,%: C 50.90; H 4.64;
    N 10.97; S 17.00. Example 8. 2,6-Dimethyl-4oxy-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-di25 oxide.
    4.0 g (14 mmol) of methyl 4-hydroxy-2,6-dimethyl-2H-1, methyl efcra 4-hydroxy-2H-1, 2-benzothiazine-3-carboxylic acid and 2.0 g (17 mol) of 2-amine. o-5-methylthiazole in 200 ml of anhydrous
    30 xylene for 24 h, heated with, reflux. After cooling, the crystallized precipitate is filtered off. . By recrystallization from ethylene chloride, 3.6 g (70%) of 2,6-dimethyl-4-hydroxy-M- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1 is obtained, 1-dioxide; m.p. 2 ° C (decomp.);
    1 H-NMR (CDC1, + TFA): cG 7.98 0 (brc.l, 5-H), 7.92 (d.1, J 4 Hz, 8-H), 7.7 (Lg.d. 1, J 4 Hz, 7-H). 7.47 (d.1 ,. J 1 Hz, 4-H), 2.96 (s, 3, M-CH3) and 2.6 (Lg s, 6.6-CH and 5-CH3).
    5 Calculated: C 49.30; H 4.14; N 11.50; S 17.55. C f 5 0-452 (365.45) Found: C 49-, 40; H 4.24;
    N 11.45; S 17.35.
    Q If o-dichlorobechzol, tetrahydronaphthalene or di: ethylene glycol dimethyl ether is used as a solvent instead of xylene, then the same compound is obtained in 70, 60 or 75% yields, respectively. The starting compound is obtained as follows.
    45 g (0.23 mol) of 5-methyl-benzisothiazol-3 (2H) -one-1,1-dioxide was added to a solution of 9.16 g (0.23 mol) of sodium hydroxide in 500 ml of water and brought to until boiling. The solution is filtered and evaporated in vacuo. The residue is shifted several times with toluene, toluene is distilled off each time, and then 5 ml of dimethyl sulfoxide and 34.72 g (0.32 mol) of chloroacetic acid methyl ester are added. The reaction mixture is heated for three hours before and after cooling, is added to a solution of 42 g of sodium acetate in 300 ml of water. The precipitate is sucked off, washed with water, again treated with 200 ml of water, sucked off and dried. 48.8 g (79%) of 5-methyl 3-oxo-benzisothiazol-2- (3N) acetic acid methyl ester 1,1-dioxide are obtained; mp, 115s 38 g (0.14 mol) of 5-methyl-3-oxo-benH methyl ester 1,1-dioxide zizothiazol-2- (3N) acetic acid and 23.9 g (0.44 mol) Sodium methylate is mixed and, after thoroughly mixing, 250 ml of anhydrous toluene and then 42 ml of anhydrous tert-butanol are added. Then the yellow reaction mixture is heated to 65 ° C for one hour. After cooling, the reaction mixture is poured into ice water and mixed with ether. The aqueous phase is extracted twice with ether and then carefully acidified with concentrated hydrochloric acid. After extraction by ether, the ether phase is washed with water, dried and evaporated. The residue is recrystallized from ethyl acetate and 27.6) 1.1 methyl 4-oxy-b-methyl 2H-1,2-benzothiazine-3-carboxylic acid methyl ester is obtained, m.p. 169 ° С, 25 g (0.092 mol) 1,1-diox, 4-hydroxy-6 --- methyl-2H-1, 2-benothiazine-3-carboxylic acid methyl ester and 36.9 g (0, 26 mol of methyl iodide are suspended in 185 ml of tetrahydrofuran and a solution of 5.2 g (0.092 mol) of potassium hydroxide in 100 ml of water is added. After 24 hours, another 20 g of methyl iodide is added and, after stirring for 24 hours, the methyl ether 2, b-dimethyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxylic acid evaporates. acid, washed and dried. Poh accounted for 9.9 g (38%) with m.p. . At capacity 9, 9.7.7 Dimethyl-4-hydroxy-N (5-methyl-2-thiazole1) -2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. 2.83 g (0.01 mol) of 2,7 dinmethyl-4-hydroxy -2H-1,2-benzothiazin-3 carboxylic acid methyl ester 1,1-dioxide and 1.25 g (0.011 mol) of 2- amino-5-methylthiazol, analogously to Example 8, is heated in xylene to obtain 3.1 g (84%) 2, 7 Dimethyl-4-hydroxy-N- (5 methyl-2-thiazolyl) 2H-1,2 benzothiazine -3-carboxamide 1,1-dioxide, so pl. 228C (from xylene. In the reaction in toluene, the same product is obtained with a yield of 70%. Calculated,%: C 49.30; AND 4.14; N 11.50; S 17.55. (365.45) Found,% : C 49.25; H 4.08; N 11.41; S 17.62. The starting compounds are prepared as follows: b-Methyl-benzisothiazol-3 (2H) -on1, 1-dioxide similarly to 5-methyl-benzothiazole -3 (2H) -one-1,1-dioxide (see Example 8) with sodium hydroxide is converted into methyl acetic ester chloroacetic acid methyl acetate 3-methyl b-3-3-oxo-benzisioazol-2 (3N) - acetic acid (m.p. 139-c from methanol). After re-grouping with sodium methoxide toluene / tert-butanol, I get 4-hydroxy7-methyl-2H-1, 2-benzothiazine-3-carboxylic acid 1,1-dioxide, and from this compound and methyl iodide, 2,7-dimethyl 4-hydroxy-2H methyl ester is obtained -1, 2 benzthiazine-3-carboxylic acid {mp. 183 ° C), Example 10. 4-Oxy-6-methoxy-2-methyl-N- (5-methyl-2-thiazolyl) -2N-1 , 2-benzothiazine-3-carboxamide-1,1-DIOXyl. 5.2 g (0.017 mol of 4-hydroxy-b-methoxy-2-methyl-2I-1, 2-benzothiazn-3-carboxylic acid methyl ester 1,1-dioxide and 2.2 g (0.019 mol) of 2-amino -5-methylthiazole in 200 ml: xylene is heated under reflux for 24 h. After cooling, the crystals are filtered and recrystallized from tetrahydrofuran to give 5.8 g (89%) of 4-oxy-6-methoxy-2-methyl-H- (5 -methyl-2-thiazolyl) -2H-1,2-benzothiazin-3 carboxamide-1, 1-dioxide with mp. 260 ° C. (SOSTS + TPA): (f 7.95 (d, 1, J 4 Hz, 8 - H), 7.62 (d, l, J 1, 5-H), 7.45 (d, l, J - 1 Hz, 4-i), 7.35 (dd, 1 , J: 4 Hz and J 1, 4.00 (s, 3, OCH), 2.95 5 Hz, bH), (s, 3, N-CHj) and 2.55 (d, 3, J 1 Hz, 5-GIi). Calculations leno,%; C 47.23; H 3.96;; G11.02; S 16.81; (381.45) Found; C 47.50; H 4.10; N 10.87; S 16, 58. The starting compound is prepared as follows: 5-Methoxy-benzisothiazole 3 (2H), 1-dioxide, similarly to 5-methylbenzisothiazol-3 (2H) -one-1,1-dioxide (see Example 8) with sodium hydroxide and. chloroacetic acid methyl ester is converted to 1.1 methoxy methyl ether 3 methoxy-3-oxo-benzisothiazole 2 (3N) -acetic acid. After rearrangement with sodium methoxide in toluene / tert-butanol, 4-hydroxy 6-methoxy-2n 1, 2-benzothiazine-3-carboxylic acid methyl ester 1,1-dioxide (mp. From ethyl acetate / cyclohexane) and subsequent methylation are obtained. its methyl iodide gives methyl 4-hydroxy-6-methoxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid slot 1,1-dioxide, m.p. 164 ° C. Example 11. 6-Chloro-4-hydroxy-2-methyl-M- (5-methyl-2-thiazolyl) -2H-1, 2-benzothiazine-3-carboxamide-1,1-dioxide. 5.0 g (16.5 mmol) of b-chloro-4-hydroxy-2methyl-2H-1, 2-benzothiazine-3-carboxylic acid methyl ether 1,1-dioxide and 2.1 g (18.5 mmol) 2-amino-5-methylthiazole in 300 ml of anhydrous xylene for 24 hours in a Soxhlet apparatus equipped with a 4-A molecular sieve is heated under reflux. After cooling, the crude product crystallized out from the crude product and was recrystallized from dioxane. 4.9 g {77%) b-chloro-4-hydroxy-2 methyl-M- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide is obtained. with mp (decomp.) 1 H-NMR (/ On / -DMSO): (f 8.05, and 7.9 (m, 3.5-H, 7-H and 8-H 7., 3b ( d, 1, J 1 Hz, 4-H), 2.95 (s, 3,. N-CHg), 2.35 (d, 3.0 1 Hz 5-СНз) and 2 exchange protons. Calculated,% : C 43.58; H 3.13; C1 9D9; N 10.89; S 16.62. CH i ASce (385.86) Found, I: C 43.42; H 3.21; C1 9.28 N, 10.68, S 16.60 The preparation of the starting compound is carried out as follows: 43.6 g (0.18 mol) of sodium salt 5-chloro-benzisothiazole-3 (2H) -one-1,1-dioxide ( obtained from 5-chloro-benzisothiazole-3 (2H) -one-1,1-dioxide and caustic soda solution) and 35 ml (0.21 mol) of methyl ester Chloro acetic acid in 100 ml of dimethyl sulfoxide is heated to three hours after. After cooling, 80 ml of dimethyl sulfoxide is removed from the reaction mixture by distillation in a vacuum. The residue is added to 700 ml of water containing 100 g of sodium acetate. The precipitated 1,1-dioxide 5-chloro-3-oxo-benzisothiazole-2- (3N) acetic acid methyl ester is sucked off, washed and dried; receive 31.1 g (60%) with so pl. . 24.5 g (84.5 mmol) of this compound and 13.5 (253 mmol) of sodium methylate in 190 ml of anhydrous toluene with the addition of 17 ml of dry tert-butanol are heated to 80 ° C for 45 minutes. The cooled reaction mixture was poured into ice water and extracted with ether. The aqueous phase is acidified with hydrochloric acid. The white precipitate is filtered off, washed three times with water and dried. Obtain 14.6 g (60%) of 6-chloro-4-hydroxy-2H-1,2-benzothiazine-Zcarboxylic acid 1,1-dioxide methyl ester with m.p. (different). Out of 14.5 (50 mmol) of 6-chloro-4-hydroxy-2H-1, methyl 2-benzothiazine-3-carboxylate ether, 21.3 g (150 mmol) of methyl iodide and 50 ml of IN solution of sodium hydroxide in 165 ml of methanol, 12.35 g (81%) of 6-chloro-4-hydroxy-2-methyl-2H-1,2-benzohiazin-; 3-carboxylic acid methyl ester 1,1-dioxide with 3 tons is obtained. square 201 ° C. Example 12. 7-Fluoro-4-hydroxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1, 2-benzothiazine-3-carboxamide-1,1-dioxide. 0.29 g (1 mmol) of 7-fluoro-4-hydroxy-2-methyl-2H-1, 2-benzothiazine-3-carboxylic acid methyl ether 1,1-dioxide and 0.125 g (1.1 mmol) of 2- Amino-5-methylthiazole in 50 ml of xylene is heated under reflux for 24 hours. The reaction mixture is evaporated to dryness in vacuo and the residue is recrystallized from xylene / cyclohexane. 0.21 g (57%) of 7-fluoro-4-hydroxy-2-methyl-M-5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carbox .mide-1,1- is obtained dioxide with so pl. 233C. If benzene is used as a solvent, then after heating for 30 hours, this compound is obtained in the same yield. Calculated,%: C 45,52; H-3.27; N 11.38; S 17.36. C 4H- / 2 2 - (369.40) Found,%: C 45.40; H 3.18; N 11.42; S 17.18. The original connection get bare-. in this way. 6-Fluoro-benzisothiazol-3 (2H) -one-1,1 dioxide, similarly to 5-chloro-benzisoiazole-3 (2H) -one-1,1-dioxide (see Example 11), with sodium hydroxide solution and ethyl ester Chloroacetic acid is converted into b-fluoro-3-oxo-benzisoiazole-2 (3N) -acetic acid methyl ester 1,1-dioxide. mp. , from isopropanol / petroleum ether). After regrouping with methylate. Atri receive 7-fluoro-4-hydroxy-2H-1,2-benothiazine-3-carboxylic acid methyl ester 1,1-dioxide. mp. 206C, and from this compound and ethyl iodide, 7-fluoro-4-hydroxy-2-meIL-2H ethyl 1-dioxide 1, 2-benzothiazine-3-carboxylic acid ester is obtained (mp. 191 ° C from ethylene chloride). PRI mep 13. 4-Oxy-2-methylN- (5-methyl-2-thiazolyl) -2H-1,2-benzoiazine-3-carboxamide-1, 1-dioxide. Prepared from ethyl 4-hydroxy-2-methyl-2H-1,2-benothiazine-3-carboxylic acid 1,1-dioxide and 2-amino-5-methylthiazole, similar to Example 1, but using o-dichlorobenzene as a solvent with yield 76% and with so pl. 254C (decomposition from ethylene chloride. Calculated,% g 4 1b2. Found,%: Example 14. 4-Oxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazin-3 -carboxamide-1, 1-dioxide. 1.23 g (4.5 mmol) of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide chloride are dissolved in 10 ml of dimethylformamide and 2-aminr-5-methylthiazole (9 mmol) are added in portions. The reaction mixture is stirred for 24 hours at room temperature and then mixed with 40 ml of water. The mixture is stirred for 20 minutes at room temperature and the precipitate is filtered , washed and dried. from ethylene chloride I get 0.4 g (25%) of 4-rxy-2-methyl-M- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide c t, pl. 254С (decomp.). Calculated,%: C 47.85; H 3.73; N 11.96; S 18.21 (351.40). Found,%: C 47.75; H 3 , 88; N 11.69; S 17.98. Example 15. 4-Oxy 2-methyl H-- (5-methyl-2-thiazolyl) -2H-1,2-ben zothiazin-3 carboxamide-1,1 -dioxide .1.0 g (3 mmol) 4-hydroxy-2-methyl M-phenyl-2H-1, 2-benzothiazi "-3-carbo xamide-1,1-dioxide with 1.15 g (10 mmol) 2-amino-5-methylthiazole and .0.1 g of p-toluenesulfonic acid in 250 m of xylene are heated under reflux for 72 hours. After cooling, the reaction mixture is washed with 2m hydrochloric acid and then with water, dried and evaporated in vacuo. About Tat puchashot chromatography on a column (Merck silica gel, grain size: 0.2-0.5 lm, eluate: chloroform / ethanol, 95: 5) and get 0.25 g (24%) 4-hydroxy-2 -methyl-M -. (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide, m.p. 254s (decomp.) Of ethylene chloride. Calculated,% s With 47.85; H 3.73; N, 11.96; S 18.21. (351.40) Found, 1: C, 47.70; H 3.78; M 11.86; S 18.01, Example 16. 4-hydroxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1,2-benz thiazine-3-carboxamide-1,1-dioxide. Prepared from 4-hydroxy-2-methyl-2H-1, -benzothiaen-3-carboxamide, 1-dioxid and 2-amino-5-methylthiazole in the presence of p-toluenesulphonic acid, as in Example 15, in 48% yield, m.p. 254C (from ethylene chloride). C 47.85; H 3.73; Calculated,%: N 11.96; S 18.21, (351.40). C-47.80; H Found,%: 12.00; S 18.05. N P im im 17. 4-Oxy-2-methylN- (5-methyl-2-thiazolyl) -2H-1,2-benzoiazine-3-carboxamide-1, 1-dioxide. To 0.2 g (0.55 mmol) of 4-methoxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1,2benzothiazine-3-carboxamide-1, 1-Dixide, add 1 ml of ice acetic acid and 0.5 ml of 48% hydrobromic acid. After 4 hours, the reaction mixture is heated for two ases on a water bath and then evaporated to dryness in vacuo. The residue is dissolved in methylene chloride and washed with water. After evaporation and drying, 0.1 g of 4-hydroxy-2-methyl-M- (5-methyl-2-thiazolyl) -2H-1, 2-benzothiazine-3-carboxamide-1,1-dioxide (52%) is obtained m.p. (pl. from ethylene chloride). Calculated,%: C 47, 85; H 3.73; N 11.96; S 18.21, 3 (351.40) Found. %: C, 47.82; H 3.67; N 11.80; S 18.01. The original compound was prepared as follows. .26.9 g (0.1 mol) of methyl 4-hydroxy-2-methyl-2H-1, 2-benzothiazine-3-carboxylic acid 1,1-dioxide methyl ester, 85.1 g (0.616 mol) of potassium carbonate and 71 g (0.5 mol) of methyl iodide in 1000 ml of acetone is heated for 16 h with a condenser condenser. Every four hours, 14 g (0.1 mol) of methyl iodide was added to the boiling reaction mixture. Then the reaction mixture is stirred for 12 hours at room temperature. The precipitate formed is filtered and washed with acetone. The filtrates are evaporated in vacuo and after recrystallization from carbon tetrachloride, 234.5 g (83%) of 4-methoxy-2-methyl-2H-1, 2-benzothiazine-3-carboxylic acid methyl ester 1,1-dioxide are obtained. 78C. A 7.8 g (28 mmol) - 4-methoxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid methyl ester 1,1-dioxide is dissolved in 75 ml of ethanol and mixed with 42 ml of IN solution caustic potash. The reaction mixture is heated under reflux for six hours, cooled, stirred. It is stirred overnight at room temperature and then evaporated in vacuo. The residue is dissolved in water and taken up in ether. The aqueous phase is cooled, acidified and the resulting precipitate is filtered off and washed with water. 6.3 g (84%) of 4-methoxy-2-methyl-2H-1,2-benzothiazium-3-carboxylic acid 1,1-dioxide are obtained with a mp. . 6.2 g (23 mmol) of 4-methoxy-2-methyl-2H-1, 2, 2-benzothiazine-3 1,1-dioxide
    权利要求:
    Claims (4)
    [1]
    Claim
    1. The method of obtaining 4-hydroxy-2H-1,2-beneotiaein-3-carboxamide-1,1-dioxides of the general formula / O 0 where in an inert organic solvent or in excess of an amine of the general formula ΙΪΙ at a temperature of from 20 to 200 ° FROM. If necessary, the protective • alkyl group is removed, followed by isolation of the target product in free form or in the form of a salt with an inorganic or organic base.
    [2]
    2. The method according to claim 1, characterized in that in the case of using a carboxylic acid ester of the formula And the alcohol formed in the process is removed by azeotropic distillation.
    [3]
    3. The method of pop. 1, characterized in that in the case of using a carboxylic acid amide of the formula II, the process is carried out in xylene at the boiling point in the presence of catalytic amounts of p-toluenesulfonic acid.
    [4]
    4. The method of pop. 1, characterized in that in the case when in the compound of formula II is a protective alkyl group, the removal of the protective group is carried out by · treatment with mineral acid at a temperature of
    0 to 100 ° C or treatment with boron halogenide at a temperature of minus 80 to plus 80 ° C.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU841588A3|1981-06-23|Method of preparing 1-oxy-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxides or their salts with inorganic or organic bases
    FI72719B|1987-03-31|SYNTESFOERFARANDE FOER PIROXIKAM SAMT MELLANPRODUKT.
    KR100359959B1|2003-01-14|Preparation method of benzoic acid derivative intermediate and benzothiophene
    CA2368815A1|2000-10-26|Novel synthesis and crystallization of piperazine ring-containing compounds
    CA1077934A|1980-05-20|Process for the preparation of 3,4-dihydro-2-methyl-4-oxo-2h-1,2-benzothiazine-3-carboxylic acid-1,1-dioxide and its use as an intermediate
    RU2194706C2|2002-12-20|Method of synthesis of 1-[[[5-|-2-furanyl]methylene]amino]- 3-[4-|butyl]-2,4-imidazolidinedione dihydrochloride
    US2659732A|1953-11-17|Quaternary ammonium salts of dialkyl aminoalkyl xanthene-9-carboxylates and the production thereof
    US3238220A|1966-03-01|3-hydroxy-benzisoxazoles and their production
    RU2194705C2|2002-12-20|Method of synthesis of 1,3-disubstituted 4-oxo-cyclic ureas
    EP0273321B1|1992-04-22|7-bromo-beta-carboline compound and method for producing same
    JP2668816B2|1997-10-27|Process for producing benzothiadiazole derivative
    EP0146102B1|1989-03-01|Process for preparing benzothiazine compounds
    CA1111034A|1981-10-20|Azathianaphthalene derivatives, process for their manufacture, pharmaceutical preparations containing them and their use
    DK141502B|1980-03-31|Process for preparing a 7-acylamido-3-methyl-3-cephem-4-carboxylic acid ester.
    KR890001241B1|1989-04-28|Process for preparing 4-acetyl isoquinolinone
    GB2092130A|1982-08-11|4-Oximino-1,2,3,4- tetrahydroquinoline Derivatives
    US3378592A|1968-04-16|Process for the production of 3, 4-dihydroxybenzyloxyaminehydrobromide
    KR860000767B1|1986-06-23|Process for preparing nizatidine
    US3210348A|1965-10-05|6h-6-trichloromethylmercapto-dibenzo[c, e][1, 2]thiazine 5, 5-dioxide compounds
    AU680989B2|1997-08-14|Method of preparing 6-aryloxymethyl-1-hydroxy-4-methyl-2-pyridones
    JP4336913B2|2009-09-30|Method for producing amide derivative
    JP4351316B2|2009-10-28|Benzoxazole derivatives and process for producing the same
    KR820000368B1|1982-03-25|Nevel process for preparing thiazole derivatives
    US4683306A|1987-07-28|Process for the preparation of 3,4-dihydro-2-substituted-2H-1,2-thiazine-carboxylic acid 1,1-dioxide derivatives
    US3346638A|1967-10-10|Alpha-phenyl-2-amino-benzylmercaptanes
    同族专利:
    公开号 | 公开日
    ES8802454A3|1988-06-16|
    CS410091A3|1992-06-17|
    AU522538B2|1982-06-10|
    JPS6324997B2|1988-05-23|
    DK149344B|1986-05-12|
    AU4253078A|1979-06-21|
    EP0002482A1|1979-06-27|
    CA1102802A|1981-06-09|
    PT68915A|1979-01-01|
    JPS5492976A|1979-07-23|
    GR65626B|1980-10-15|
    DD140354A5|1980-02-27|
    FI61896C|1982-10-11|
    NZ189186A|1981-03-16|
    NO150203B|1984-05-28|
    ATA863078A|1981-06-15|
    IE48042B1|1984-09-05|
    HU175846B|1980-10-28|
    LU88557I2|1995-03-21|
    PL115756B1|1981-04-30|
    EP0002482B1|1981-01-07|
    MX9202949A|1992-07-01|
    ES475677A1|1979-04-16|
    NO150203C|1984-09-05|
    NL940002I1|1994-03-16|
    FI783867A|1979-06-17|
    BG60475B2|1995-04-28|
    DK562078A|1979-06-17|
    NL940002I2|1997-05-01|
    DE2860445D1|1981-02-26|
    US4233299A|1980-11-11|
    YU294978A|1982-10-31|
    PL211753A1|1979-08-13|
    IE782482L|1979-06-16|
    FI61896B|1982-06-30|
    NO784231L|1979-06-19|
    RO75792A|1981-02-28|
    AT365589B|1982-01-25|
    IL56206A|1982-04-30|
    CS202515B2|1981-01-30|
    BG33286A3|1983-01-14|
    DE2756113A1|1979-06-21|
    IL56206D0|1979-03-12|
    ES550377A0|1988-06-16|
    DK149344C|1986-10-13|
    NO1997002I1|1997-01-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3591584A|1968-08-27|1971-07-06|Pfizer|Benzothiazine dioxides|
    US3853862A|1973-04-23|1974-12-10|Pfizer|Production of 4-hydroxy-1,2-benzothiazine-3-carboxamides|
    US3925371A|1974-09-23|1975-12-09|Mcneilab Inc|Benzothiazine-1,1-dioxides|
    US3892740A|1974-10-15|1975-07-01|Pfizer|Process for the production of carboxamides of oxo-1,2-benzothiazine-1,1-dioxides|
    US4074048A|1976-05-10|1978-02-14|Warner-Lambert Company|Process for the preparation of 4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides|
    US4100347A|1976-06-10|1978-07-11|Pfizer Inc.|3,4-Dihydro-2-methyl-4-oxo-2H-1,2-benzothiazine-3-carboxylic acid-1,1-dioxide|US4434164A|1981-06-01|1984-02-28|Pfizer Inc.|Crystalline benzothiazine dioxide salts|
    DE3217315C2|1982-05-08|1986-05-22|Gödecke AG, 1000 Berlin|Medicinal preparations containing oxicam derivatives|
    CA1203806A|1982-05-31|1986-04-29|Susumu Nakagawa|2-oxo-1-azetidinesulfonic acid derivatives, processfor production thereof, and use thereof|
    DE3237473A1|1982-10-09|1984-04-12|Dr. Karl Thomae Gmbh, 7950 Biberach|NEW 4-HYDROXY-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    DE3435843C2|1984-09-29|1988-10-27|Goedecke Ag, 1000 Berlin, De|
    DE3437232A1|1984-10-10|1986-04-17|Mack Chem Pharm|STABILIZED INJECTION SOLUTIONS FROM PIROXICAM|
    JPS61161281A|1985-01-10|1986-07-21|Grelan Pharmaceut Co Ltd|1,2-benzothiazine-3-carboxamide derivative|
    US4803197A|1987-01-12|1989-02-07|Ciba-Geigy Corporation|2,1-benzothiazepine-2,2-dioxide-5-carboxylic acid derivatives|
    WO1997046532A1|1996-06-03|1997-12-11|Boehringer Ingelheim Pharmaceuticals, Inc.|2-benzyl-4-sulfonyl-4h-isoquinolin-1,3-diones and their use as anti-inflammatory agents|
    US20040072889A1|1997-04-21|2004-04-15|Pharmacia Corporation|Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia|
    US6284269B1|1997-08-27|2001-09-04|Hexal Ag|Pharmaceutical compositions of meloxicam with improved solubility and bioavailability|
    US6733767B2|1998-03-19|2004-05-11|Merck & Co., Inc.|Liquid polymeric compositions for controlled release of bioactive substances|
    EP0945134A1|1998-03-27|1999-09-29|Boehringer Ingelheim Pharma KG|New galenic formulations of meloxicam for oral administration|
    US6407124B1|1998-06-18|2002-06-18|Bristol-Myers Squibb Company|Carbon substituted aminothiazole inhibitors of cyclin dependent kinases|
    US20080102121A1|1998-11-02|2008-05-01|Elan Pharma International Limited|Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone|
    US6649645B1|1998-12-23|2003-11-18|Pharmacia Corporation|Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia|
    IT1308633B1|1999-03-02|2002-01-09|Nicox Sa|NITROSSIDERIVATI.|
    WO2001037838A1|1999-11-24|2001-05-31|Wakamoto Pharmaceutical Co., Ltd.|Ophthalmic aqueous preparation|
    DE10030345A1|2000-06-20|2002-01-10|Boehringer Ingelheim Vetmed|Highly concentrated stable meloxicam solutions|
    US20020035107A1|2000-06-20|2002-03-21|Stefan Henke|Highly concentrated stable meloxicam solutions|
    JP2004503601A|2000-07-13|2004-02-05|ファルマシア・コーポレーション|Use of COX-2 inhibitors in the treatment and prevention of ocular COX-2-mediated diseases|
    IT1318674B1|2000-08-08|2003-08-27|Nicox Sa|DO IT FOR INCONTINENCE.|
    US20030008870A1|2001-02-02|2003-01-09|Joel Krasnow|Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dysmenorrhea|
    ITMI20010733A1|2001-04-05|2002-10-07|Recordati Chem Pharm|USE OF ISOENZIN COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE|
    AR038957A1|2001-08-15|2005-02-02|Pharmacia Corp|COMBINATION THERAPY FOR CANCER TREATMENT|
    GB0124124D0|2001-10-08|2001-11-28|Medical Res Council|Methods of treatment|
    ES2223209B1|2001-12-11|2005-10-01|Esteve Quimica, S.A.|NEW CRYSTAL FORMS OF MELOXICAM AND PROCEDURES FOR PREPARATION AND INTERCONVERSION.|
    DE10161077A1|2001-12-12|2003-06-18|Boehringer Ingelheim Vetmed|Highly concentrated stable meloxicam solutions for needleless injection|
    US20040001883A1|2002-03-30|2004-01-01|Boehringer Ingelheim International Gmbh|Meloxicam suppositories|
    EP1348436A1|2002-03-30|2003-10-01|Boehringer Ingelheim International GmbH|Meloxicam suppositories|
    GB0208785D0|2002-04-17|2002-05-29|Medical Res Council|Treatment methtods|
    EP1494715A1|2002-04-17|2005-01-12|Medical Research Council|Fp receptor antagonists or pgf2 aplha antagonists for treating menorrhagia|
    DE10223013A1|2002-05-22|2003-12-04|Boehringer Ingelheim Int|Use of meloxicam for the relief of organ injuries during organ surgery or transplantation|
    US6960611B2|2002-09-16|2005-11-01|Institute Of Materia Medica|Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof|
    TW200418487A|2002-09-17|2004-10-01|Nippon Boehringer Ingelheim Co|Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.|
    US8992980B2|2002-10-25|2015-03-31|Boehringer Ingelheim Vetmedica Gmbh|Water-soluble meloxicam granules|
    US20040082543A1|2002-10-29|2004-04-29|Pharmacia Corporation|Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain|
    US20040147581A1|2002-11-18|2004-07-29|Pharmacia Corporation|Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy|
    DE60332387D1|2002-12-13|2010-06-10|Warner Lambert Co|ALPHA-2-DELTA LIGAND FOR THE TREATMENT OF LOWER HARNESS SYMPTOMS|
    WO2004071508A1|2003-02-14|2004-08-26|Medical Research Council|Ip receptor antagonists for the treatment of pathological uterine conditions|
    US8512727B2|2003-03-03|2013-08-20|Alkermes Pharma Ireland Limited|Nanoparticulate meloxicam formulations|
    US20100297252A1|2003-03-03|2010-11-25|Elan Pharma International Ltd.|Nanoparticulate meloxicam formulations|
    US20040220155A1|2003-03-28|2004-11-04|Pharmacia Corporation|Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith|
    US20050014729A1|2003-07-16|2005-01-20|Pharmacia Corporation|Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith|
    US20050119262A1|2003-08-21|2005-06-02|Pharmacia Corporation|Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent|
    WO2005023189A2|2003-09-03|2005-03-17|Pharmacia Corporation|Method of cox-2 selective inhibitor and nitric oxide-donating agent|
    EP1708718A1|2004-01-22|2006-10-11|Pfizer Limited|Triazole derivatives which inhibit vasopressin antagonistic activity|
    EP1568369A1|2004-02-23|2005-08-31|Boehringer Ingelheim Vetmedica Gmbh|Use of meloxicam for the treatment of respiratory diseases in pigs|
    WO2005105779A1|2004-04-28|2005-11-10|Pfizer Limited|3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor|
    DE102004021281A1|2004-04-29|2005-11-24|Boehringer Ingelheim Vetmedica Gmbh|Use of meloxicam formulations in veterinary medicine|
    US8431110B2|2005-05-23|2013-04-30|Hmi Medical Innovations, Llc.|Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators|
    ES2777924T3|2004-05-23|2020-08-06|Hmi Medical Innovations Llc|Teramutein modulators|
    DE102004030409A1|2004-06-23|2006-01-26|Boehringer Ingelheim Vetmedica Gmbh|New use of meloxicam in veterinary medicine|
    ITMI20041918A1|2004-10-11|2005-01-11|A M S A Anonima Materie Sintetiche Affini Spa|MELOXICAM PURIFICATION PROCESS|
    HU227359B1|2004-12-18|2011-04-28|Egis Gyogyszergyar Nyilvanosan Mikodi Ruszvunytarsasag|Process for producing meloxicam and meloxicam potassium salt of high purity|
    JP5577021B2|2005-02-17|2014-08-20|アボット・ラボラトリーズ|Transmucosal administration of pharmaceutical compositions for treating and preventing disorders in animals|
    US20080234252A1|2005-05-18|2008-09-25|Pfizer Inc|Compounds Useful in Therapy|
    JP2009523408A|2005-11-23|2009-06-25|ジェラルド・エム・ハウシー|Group of compounds and methods for identifying, synthesizing, optimizing and analyzing protein modulators|
    BRPI0617208A2|2005-09-30|2011-07-19|Boehringer Ingelheim Vetmed|pharmaceutical preparation containing meloxicam|
    KR101402592B1|2006-03-06|2014-06-17|에스케이바이오팜 주식회사|Transdermal Composition Using Piroxicam-Inorganic Complex and Patch System Comprising the Same|
    GB2438287A|2006-05-19|2007-11-21|Norbrook Lab Ltd|Stable aqueous suspension|
    US20070281927A1|2006-06-06|2007-12-06|Shanthakumar Tyavanagimatt|Anti-inflammatory and analgesic compositions and related methods|
    GB2443891B|2006-11-20|2009-04-08|Norbrook Lab Ltd|Process for the purification of meloxicam|
    CN101600458A|2006-12-22|2009-12-09|瑞蔻达蒂爱尔兰有限公司|Adopt α 2The therapeutic alliance of the lower urinary tract disorders of 2-delta ligand and NSAID|
    EP2120959A4|2007-01-23|2010-05-26|Reddys Lab Ltd Dr|Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia|
    EP2244712B1|2008-01-22|2015-08-05|Thar Pharmaceuticals Inc.|In vivo studies of crystalline forms of meloxicam|
    US8227451B2|2008-11-12|2012-07-24|Auspex Pharmaceuticals|Phenylacetic acid inhibitors of cyclooxygenase|
    TR200809200A1|2008-12-01|2009-12-21|Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇|Pharmaceutical formulations containing meloxicam|
    GB0903493D0|2009-02-27|2009-04-08|Vantia Ltd|New compounds|
    WO2011026080A1|2009-08-31|2011-03-03|Wilmington Pharmaceuticals, Llc|Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain|
    JP5559339B2|2009-10-12|2014-07-23|ベーリンガーインゲルハイムフェトメディカゲゼルシャフトミットベシュレンクテルハフツング|Container for compositions containing meloxicam|
    US20110218191A1|2010-03-03|2011-09-08|Boehringer Ingelheim Vetmedica Gmbh|Use of meloxicam for the long term-treatment of kidney disorders in cats|
    AU2010347598B2|2010-03-03|2014-11-27|Boehringer Ingelheim Vetmedica Gmbh|Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats|
    US9795568B2|2010-05-05|2017-10-24|Boehringer Ingelheim Vetmedica Gmbh|Low concentration meloxicam tablets|
    AU2012296925A1|2011-08-12|2014-02-06|Boehringer Ingelheim Vetmedica Gmbh|Taste masked pharmaceutical composition|
    CN102775401B|2012-08-15|2015-01-07|青岛农业大学|Synthesis method of meloxicam|
    US10821181B2|2015-02-10|2020-11-03|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10758618B2|2015-02-10|2020-09-01|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US11219626B2|2017-06-29|2022-01-11|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10821182B2|2017-06-29|2020-11-03|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10695430B2|2015-02-10|2020-06-30|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10780166B2|2015-02-10|2020-09-22|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10729774B1|2015-02-10|2020-08-04|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US11110173B2|2015-02-10|2021-09-07|Axsome Therapeutics, Inc|Pharmaceutical compositions comprising meloxicam|
    US10722583B2|2015-02-10|2020-07-28|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10561664B1|2017-01-04|2020-02-18|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10758617B2|2017-06-29|2020-09-01|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10695429B2|2015-02-10|2020-06-30|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US11013806B2|2015-02-10|2021-05-25|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10933137B2|2015-02-10|2021-03-02|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US11013805B2|2015-02-10|2021-05-25|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US11045549B2|2015-02-10|2021-06-29|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10799588B2|2015-02-10|2020-10-13|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10688185B2|2017-06-29|2020-06-23|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10780165B2|2015-02-10|2020-09-22|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10933136B2|2015-02-10|2021-03-02|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10729773B2|2015-02-10|2020-08-04|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10940153B2|2017-01-04|2021-03-09|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10702602B2|2015-02-10|2020-07-07|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10918722B2|2017-06-29|2021-02-16|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US11207327B2|2017-01-04|2021-12-28|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10905693B2|2017-01-04|2021-02-02|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10729696B2|2017-01-04|2020-08-04|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10987358B2|2017-06-29|2021-04-27|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US11185550B2|2017-06-29|2021-11-30|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10729697B2|2017-01-04|2020-08-04|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10894053B2|2017-01-04|2021-01-19|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US11266657B2|2017-01-04|2022-03-08|Axsome Therapeutics, Inc.|Pharmaceutical compositions comprising meloxicam|
    US10688102B2|2017-06-29|2020-06-23|Axsome Therapeutics, Inc.|Combination treatment for migraine and other pain|
    CN108690078A|2017-03-29|2018-10-23|江苏恒瑞医药股份有限公司|A kind of benzo plug piperazine phosphate derivative, preparation method and its application in medicine|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19772756113|DE2756113A1|1977-12-16|1977-12-16|NEW 4-HYDROXY-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCTS CONTAINING THESE|
    [返回顶部]